Leukemia inhibitory factor protects the lung during respiratory syncytial viral infection by Robert F Foronjy et al.
Foronjy et al. BMC Immunology 2014, 15:41
http://www.biomedcentral.com/1471-2172/15/41RESEARCH ARTICLE Open AccessLeukemia inhibitory factor protects the lung
during respiratory syncytial viral infection
Robert F Foronjy, Abdoulaye J Dabo, Neville Cummins and Patrick Geraghty*Abstract
Background: Respiratory syncytial virus (RSV) infects the lung epithelium where it stimulates the production of
numerous host cytokines that are associated with disease burden and acute lung injury. Characterizing the host
cytokine response to RSV infection, the regulation of host cytokines and the impact of neutralizing an RSV-inducible
cytokine during infection were undertaken in this study.
Methods: A549, primary human small airway epithelial (SAE) cells and wild-type, TIR-domain-containing
adapter-inducing interferon-β (Trif) and mitochondrial antiviral-signaling protein (Mavs) knockout (KO) mice were
infected with RSV and cytokine responses were investigated by ELISA, multiplex analysis and qPCR. Neutralizing
anti-leukemia inhibitory factor (LIF) IgG or control IgG was administered to a group of wild-type animals prior to
RSV infection.
Results and discussion: RSV-infected A549 and SAE cells release a network of cytokines, including newly
identified RSV-inducible cytokines LIF, migration inhibitory factor (MIF), stem cell factor (SCF), CCL27, CXCL12 and
stem cell growth factor beta (SCGF-β). These RSV-inducible cytokines were also observed in the airways of mice
during an infection. To identify the regulation of RSV inducible cytokines, Mavs and Trif deficient animals were
infected with RSV. In vivo induction of airway IL-1β, IL-4, IL-5, IL-6, IL-12(p40), IFN-γ, CCL2, CCL5, CCL3, CXCL1,
IP-10/CXCL10, IL-22, MIG/CXCL9 and MIF were dependent on Mavs expression in mice. Loss of Trif expression
in mice altered the RSV induction of IL-1β, IL-5, CXCL12, MIF, LIF, CXCL12 and IFN-γ. Silencing of retinoic
acid–inducible gene-1 (RIG-I) expression in A549 cells had a greater impact on RSV-inducible cytokines than melanoma
differentiation-associated protein 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2), and Trif expression.
To evaluate the role of LIF in the airways during RSV infection, animals were treated with neutralizing anti-LIF
IgG, which enhanced RSV pathology observed with increased airspace protein content, apoptosis and airway
hyperresponsiveness compared to control IgG treatment.
Conclusions: RSV infection in the epithelium induces a network of immune factors to counter infection,
primarily in a RIG-I dependent manner. Expression of LIF protects the lung from lung injury and enhanced
pathology during RSV infection.
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Respiratory syncytial virus (RSV) is a major respiratory
pathogen, which typically infects the airway epithelium
[1]. Those infected with RSV, usually infants, the elderly
and immunocompromised patients but also healthy adults
[2,3], develop mild to severe cough and dyspnea [4].
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CXCL1, IL-1β, IL1-RA, IL-2, IL-6, IL-7, CXCL8/IL-8, IL-9,
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http://www.biomedcentral.com/1471-2172/15/41epidermal growth factor (EGF), hepatocyte growth factor
(HGF), granulocyte colony-stimulating factor (G-CSF),
GM-CSF, fibroblast growth factor (FGF), vascular endothe-
lial cell growth factor (VEGF) and tumor necrosis factor-α
(TNF-α) [1,7-16]. The importance of this cytokine re-
sponse is underscored by the fact that increased levels of
IL-1β, IL1-RA, IL-6, IL-7, IL-8, G-CSF, EGF and HGF are
associated with RSV infection severity [10,15]. Others have
found that SNPs in IL-19, IL-20, MUC5AC, TNFRSF1B,
C3, CTLA4, CXCL9, IL4R, and IL-7 genes are associated
with recurrent wheezing following RSV infections [17].
Although RSV-induced cytokines have been studied exten-
sively, the signaling mechanisms that regulate their expres-
sion and whether specific host cytokines contribute to
airway injury or inflammation resolution remain incom-
pletely understood.
Pathological studies demonstrate that RSV primarily
infects airway epithelial cells [18]; therefore it is conceiv-
able that a significant component of immune signaling
associated with RSV infections originates from airway
epithelial responses. Cytokines, chemokines and growth
factors are expressed in these cells in response to micro-
bial stimuli [19,20] with numerous pathogen recognition
receptors playing a major role in cytokine responses.
Pathogen recognition receptors, such as TLRs and retin-
oic acid–inducible gene-1 (RIG-I)-like receptors [21], in-
duce major signaling cascades following viral stimulation
[22]. Indeed, the viral load of RSV correlates with RIG-I
mRNA levels [23]. TLR3, −7, −8 and −9 recognize nu-
cleic acid ligands but TLR4 proteins also bind to a major
viral antigen of RSV F (fusion) protein [24]. Laboratory
of genetics and physiology 2 (LGP2) and melanoma
differentiation–associated protein-5 (MDA5) equally
could be associated with RSV-induced immune re-
sponses [25]. Additionally, ligands for nucleotide-binding
oligomerization domain-containing protein (NOD)-like
receptors (NLR), such as NOD2, enhance TLR-ligand-
induced activation and triggering such signaling cascades
are plausible means of developing RSV-specific im-
munity [26]. Therefore, RSV can induce several pathogen
recognition receptors resulting in multiple host immune
responses.
In this study we employed in vitro and in vivo
approaches to evaluate the cytokine/chemokine response
to RSV infection. Normal human small airway epithelial
(SAE) cells and A549 cells were utilized to examine 42
cytokine responses following RSV stimuli. Several newly
identified RSV-inducible cytokines (leukemia inhibitory
factor (LIF), migration inhibitory factor (MIF), stem cell
factor (SCF), CCL27, CXCL12 and stem cell growth fac-
tor beta (SCGF-β)) were induced in airways cells in vitro
and in mouse lungs during a viral infection in vivo. The
influence of TIR-domain-containing adapter-inducing
interferon-β (Trif ) and mitochondrial antiviral-signalingprotein (MAVS) signaling pathways were examined on
RSV-induced cytokine levels in mice and A549 cells.
The significance of LIF, an IL-6 cytokine family member,
expression during RSV was also determined. LIF is pri-
marily recognized for its ability to preserve the toti-
potency of embryonic stem cells [27] and is detected in
acute respiratory distress syndrome (ARDS) [28] but re-
cently LIF was described to protect the lung from injury
during pneumonia [29]. Utilizing neutralizing anti-LIF
IgG, LIF was observed to play a critical role in protect-
ing the lung from injury during RSV infection. Our find-
ings indicate that RSV infection induces a significant
host cytokine response associated with viral clearance
and airway protection.
Results
SAE and A549 cells secrete similar cytokines following
RSV stimuli
A human cytokine array was used to simultaneously de-
tect the levels of 36 different cytokines, chemokines, and
acute phase proteins in A549 cells treated with mock
and RSV for 24 hours. Protein array analysis identified
that a large number of cytokines are released from A549
cells upon RSV stimuli (Additional file 1: Figure S1). The
most striking RSV inducible cytokines were IL-6, IL-8,
MCP-1/CCL2, MIF, GROα/CXCL1, and RANTES/CCL5
(Additional file 1: Figure S1). To complement the cyto-
kine array analysis, multiplex analysis was performed to
examine 42 cytokines, chemokines and growth factors
released from A549 cells, in addition to human SAE
cells. Both SAE and A549 cells released similar cytokines
in response to RSV infection (Table 1). In both A549
and SAE cells, RSV significantly induced IL-1α, IL-1β,
IL-1RA, IL-6, IL-7, IL-8, CXCL1, CCL11, fibroblast
growth factor (FGF), G-CSF, IFN-γ, CXCL10, CCL2,
MIF, platelet-derived growth factor (PDGF-BB), TNF-α,
VEGF, LIF, CCL27, CXCL12, SCGF-β and SCF release
into media. Interestingly, SAE cells also released IL-16,
IL-18, CXCL9, CCL7 and HGF upon RSV stimulation.
A549 cells differed to SAE cells in releasing IL-10,
IL-12(p70), GM-CSF, CCL3, CCL4 and TNF-related
apoptosis-inducing ligand (TRAIL) upon RSV stimu-
lation. RSV-inducible cytokines were examined fol-
lowing stimulation with UV-inactivated RSV in A549
cells, to determine if cytokines are induced following viral
detection or viral replication. RANTES/CCL5, CXCL12,
SCGF-β, CCL27, LIF, MIF, CXCL10, CXCL1, CCL2, IL-6,
SCF, IL-7, TNF-α and G-CSF were all secreted following
stimuli with live RSV only (Figure 1). IL-8 and IFN- γ
was secreted at significantly higher levels from UV-RSV
treated cells compared to mock treated cells but at lower
levels to live RSV (Figure 1A). Therefore, RSV replication
induces a plethora of immune responses in airway epithe-
lial cells.
Table 1 RSV induces cytokine release from human airway epithelial cells
Airway epithelial cell type
SAE cells (Type I) A549 (Type II)
Cytokines (pg/ml media) Mock RSV Mock RSV
IL-1α 12.66 ± 1.76 31.75 ± 1.48* 13.52 ± 0.80 34.33 ± 4.3*
IL-1β 9.55 ± 1.17 15.50 ± 2.45* 1.28 ± 0.05 2.28 ± 0.45*
IL1-RA 40.37 ± 6.37 63.25 ± 4.82* 5.20 ± 0.37 23.28 ± 3.88*
IL-2 0.98 ± 0.28 1.44 ± 0.42 0.20 ± 0.05 0.25 ± 0.07
IL-2RA 41.65 ± 3.57 44.67 ± 2.12 36.72 ± 0.58 34.53 ± 0.55
IL-3 102.7 ± 8.85 100.2 ± 7.37 59.09 ± 3.54 58.08 ± 4.56
IL-6 2349 ± 234.6 3260 ± 153.8* 17.21 ± 0.79 534.4 ± 19.22*
IL-7 29.36 ± 4.87 55.37 ± 8.32* 17.00 ± 4.57 34.44 ± 4.15*
IL-8/CXCL8 2479 ± 154.4 5094 ± 363.5* 142.2 ± 20.70 1203 ± 83.75*
IL-10 6.89 ± 1.31 8.13 ± 0.15 5.85 ± 0.27 7.02 ± 0.24*
IL-12(p40) 193.4 ± 17.18 183.9 ± 19.78 127.2 ± 10.11 135.0 ± 19.54
IL-12(p70) 36.76 ± 5.48 36.09 ± 5.94 14.54 ± 1.29 19.86 ± 0.81*
IL-16 115.7 ± 14.5 223.5 ± 19.04* 652.1 ± 32.79 387.5 ± 45.97
IL-18 6.70 ± 0.71 11.94 ± 0.92* 6.24 ± 0.31 7.06 ± 0.37
GROα/CXCL1 8482 ± 428 11119 ± 639* 2431 ± 177.7 9473 ± 366.4*
Eotaxin/CCL11 5.16 ± 0.24 10.37 ± 0.62* 1.38 ± 0.16 3.43 ± 0.37*
FGF 6.60 ± 0.30 10.72 ± 1.41* 4.24 ± 0.51 13.92 ± 2.16*
G-CSF/CSF-3 945.6 ± 72.01 1403 ± 130.2 1.00 ± 0.79 10.16 ± 1.57*
GM-CSF/CSF-2 9.74 ± 2.99 10.04 ± 3.15 3.73 ± 0.44 7.12 ± 0.51*
M-CSF/CSF-1 73.03 ± 8.60 98.50 ± 6.41 2.90 ± 0.74 4.55 ± 0.63
IFN-α2 4.62 ± 0.32 4.97 ± 0.27 4.46 ± 0.04 4.55 ± 0.76
IFN-γ 95.39 ± 13.08 171.6 ± 12.04* 12.38 ± 1.98 81.81 ± 8.88*
MIG/CXCL9 29.01 ± 3.91 61.41 ± 2.99* 53.83 ± 5.43 104.81 ± 12.11
IP10/CXCL10 337.6 ± 93.99 10580 ± 546* 5.13 ± 0.35 1836 ± 97.5*
MCP-1/CCL2 146.2 ± 15.51 266.0 ± 42.71* 557.1 ± 30.48 1088 ± 56.54*
MCP-3/CCL7 71.68 ± 8.97 215.8 ± 17.44* 96.03 ± 10.57 78.41 ± 11.14
MIP-1α/CCL3 1.88 ± 0.12 2.38 ± 0.36 1.25 ± 0.09 16.96 ± 0.42*
MIP-1β/CCL4 1.55 ± 0.32 2.75 ± 0.45 0.77 ± 0.13 89.04 ± 7.52*
MIF 2123 ± 186.2 7435 ± 179.5* 454.0 ± 20.8 1015 ± 47.5*
PDGF-BB 6.91 ± 1.01 16.90 ± 2.98* 3.68 ± 0.59 10.23 ± 0.16*
RANTES/CCL5 206.8 ± 10.32 339.9 ± 29.54* 44.30 ± 8.53 656.9 ± 82.5*
TNF-α 16.78 ± 0.57 32.40 ± 3.27* 1.14 ± 0.12 27.83 ± 2.37*
TNF-β/LTA 21.98 ± 1.39 21.09 ± 0.78 17.59 ± 0.18 17.41 ± 0.72
VEGF 3717 ± 372.2 5256 ± 304.3* 1585 ± 108.9 3297 ± 146.2*
TRAIL 135.7 ± 13.64 209.2 ± 6.82 151.4 ± 10.16 191.9 ± 5.06*
β-NGF 23.92 ± 1.76 23.81 ± 2.23 20.50 ± 1.17 24.12 ± 2.39
LIF 114.9 ± 11.92 227.4 ± 6.7* 64.70 ± 2.41 212.7 ± 15.88*
HGF 63.33 ± 4.98 81.84 ± 1.41* 71.23 ± 1.47 69.34 ± 1.71
CTAK/ CCL27 130.5 ± 9.87 249.3 ± 9.73* 122.5 ± 2.40 211.7 ± 8.91*
SDF-1α/CXCL12 672.0 ± 31.7 1504 ± 97.33* 121.6 ± 9.61 359.4 ± 28.6*
SCGF-β 685.7 ± 32.1 1000 ± 73.1* 3575 ± 191.2 5905 ± 161.9*
SCF 19.09 ± 1.08 42.87 ± 0.18* 27.50 ± 1.52 38.66 ± 3.03*
Cytokine levels were determined in cell culture supernatants from A549 or SAE cells 24 hours post RSV challenge, by multiplex analysis. Values are represented as
mean media concentration (pg/ml) ± S.E.M. Assays were performed in triplicate from samples collected on separate days, where n = 10 samples/group. Bold
numbers denoted by *represents a p value less than 0.05 compared to mock treated cells.















































































Figure 1 RSV replication induces host cytokines production in
airway epithelial cells. A549 cells were treated with mock, RSV or
UV-inactivated RSV (UV-RSV) for 24 hours. (A-B) Secreted cytokines
were analyzed by multiplex or ELISA. Graphs are represented as mean
cytokine concentration (pg/ml) ± S.E.M, with each measurement
performed 3 times on 6 replicates/group. Samples were collected from
3 experiments performed on separate days. * and ** represent a p value
less than 0.05 compared to mock or RSV treated cells for each cytokine
target, respectively.
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expressed in the airways of mice following RSV challenge
Gene expression and BALF protein levels for MIF, LIF,
CCL27, CXCL12/SDF-1α, SCGF-β and SCF were ex-
amined in wild-type (FVB/NJ) mice 0, 1, 3, 5, 7, and
9 days post mock, RSV or UV-RSV intranasal challenge
(Figure 2), as these cytokines have not been reported in
the literature to be RSV inducible. Increased gene expres-
sion of MIF, LIF, CXCL12, SCGF-β and SCF was ob-
served following 1 day of RSV challenge (Figure 2A). RSV
inducible CCL27 was only observed 5 days post chal-
lenge. UV-inactivated RSV did not alter airway expres-
sion of these cytokines (Figure 2A). Multiplex or ELISA
was performed to examine BALF protein levels of LIF,
CCL27, CXCL12/SDF-1α, and SCF. Similarly to gene ex-
pression profiles, BALF levels of SCF, LIF, CCL27/CTAKand CXCL12/SDF-1α were all enhanced in mice exposed
to RSV infection compared to mock or UV-RSV treated
animals (Figure 2B). These new RSV-inducible targets
represent new plausible targets for investigation in the
human disease.
RSV activates TLRs and RIG-I-like receptors (RLR)
Nasopharyngeal cells from infants with RSV infection
have gene expression differences for MDA-5, RIG-1,
TLR-7, and TLR-8 [23]. Since RSV infection induces a
large repertoire of host cytokines, chemokines and
growth factors, several of the major pathogen recog-
nition receptors were profiled in each cell type to deter-
mine the potential regulators of the immune response to
RSV infection. Therefore, qPCR and immunoblots were
performed for p-IRF3(ser396), IRF3, p-TBK1(ser172),
TBK-1/NAK, RIG-I, LGP2, MDA5, MAVS, LGP2, TLR3,
TLR7, TLR8, TLR9, Trif, MyD88, IRAK1, NOD2 and
β-actin. The remaining TLR genes and other NOD
genes (NOD1 and NLXR1) were also profiled in both
cell types. A549 and SAE cells became readily infected with
RSV 24 hours after incubation (Figure 3A) and had signifi-
cant increases in RIG-I, MDA5, LGP2, NOD2, Trif, TLR2
and TLR3 gene expression in both cell types (Figure 3B).
TLR1, 6 and 10 gene expressions were also enhanced
in SAE cells following RSV infection. TLR4 gene ex-
pression was increased in A549s cells. Protein profiles
were analyzed for several of the receptors with the
greatest gene induction with RSV infection, by immu-
noblots. Increased cellular protein levels of RIG-I,
MDA5, LGP2, Trif and TLR3 were observed by immun-
blotting in both A549 and SAE cells (Figure 3C). Utilizing
densitometry analysis, no significant changes in NOD2
and TLR2 protein levels were observed in either A549 or
SAE cells possibility due to lower induction of gene ex-
pression for these targets (Additional file 1: Figure S2). To
investigate the activation status of receptors, downstream
signaling transduction analysis was performed for the
phosphorylation of IRF3, TBK1, degradation of IRAK1
and increased expression of Trif and MyD88. IRF3 and
TBK1 underwent phosphorylation following RSV infection,
confirming activation of these pathways (Figure 3C and
Additional file 1: Figure S2). Equally, increases in Trif and
decreased IRAK1 levels were observed after RSV challenge
(Figure 3C and Additional file 1: Figure S2), further con-
firming that several receptors underwent activation. Due to
the activation intensity of the RLR, activation of IRF3 and
induction of the Trif/TLR3, in vivo studies were under-
taken specifically examining the Trif and RLR pathways.
Trif and Mavs KO mice have reduced cytokine responses
to RSV challenge
Others have reported that RIG-I is essential for host
immune defenses against RSV [30,31] and our in vitro
AB
Figure 2 RSV challenge induces MIF, LIF, CCL27, CXCL12, SCGF-β and SCF airway expression. FVB/NJ mice were infected with 1x106 pfu of
RSV, UV-RSV or mock and animals were euthanized on days 0, 1, 3, 5, 7 and 9-post challenge. MIF, LIF, CTAK/CCL27, SDF-1/CXCL12, SCGF-β and
SCF (A) lung gene expression and (B) BALF protein levels were analyzed by qPCR and multiplex, respectively. Graphs are represented as relative
quantification (RQ) or BALF concentration of the mean ± S.E.M, with each measurement performed 3 times on 10 animals/group. *Represents a
p value less than 0.05 compared to mock treated mice on each corresponding day.
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highly responsive to RSV. To assess the importance of
RSV-induced TLR3 and RLR signaling on cytokine pro-
duction, wild-type (FVB/NJ), Trif and Mavs KO mice
were infected with RSV and cytokines levels were inves-
tigated by qPCR on lung tissue and multiplex analysis
on BALF. Mavs KO mice were utilized as MAVS links
RIG-I and MDA5 to antiviral effectors responses. Mice
were exposed to RSV and euthanized days 1, 3, 5, 7 and
9 days after the RSV challenge. Loss of Trif and Mavsexpression in mice did not significantly alter loss in body
weight following RSV infection compared to wild-type
mice (Figure 4A) but loss of Mavs or Trif resulted in a
greater viral load in the airway tissue on day 9 following
infection compared to wild-type mice (Figure 4B).
Cytokine release into the airways was assessed by
multiplex analysis 3 days post RSV challenge and RSV
infection yielded a significant release of IL-1α, IL-1β,
IL-2, IL-4, IL-5, IL-6, IL-12(p40), IL-12(p70), IL-13,
IL-15, IFN-γ, MCP-1/CCL2, CCL5, CCL3, CCL4, CCL11,




































































































































































































Figure 3 RSV induces multiple pathogen recognition receptors in A549 and SAE cells. (A) Representative immunofluorescence staining of
SAE and A549 cells treated with mock or RSV and stained 24 hours later with RSV F-specific monoclonal antibody. Cell lysates were examined for
viable viruses by plaque assays. (B) qPCR and (C) immunblots were performed to examine levels of pathogen recognition receptors and downstream
signaling in cells 1-day post RSV infection. Graphs are represented as (B) PFU (Log10) or (C) RQ of the mean ± S.E.M, where n = 10 replicates/group and
each assay was performed in triplicate. Each experiment was performed on samples obtained from 3 experiments from separate days. *Represents a
p value less than 0.05 compared to mock treated mice.
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into the BALF of control mice (Table 2). RSV also in-
creased gene expression of IL-27, CXCL9, CXCL10,
CXCL11, MIF and SCGF-β in the airways of control
mice 1-day post RSV challenge (Table 3). Loss of Mavs
expression subdued RSV-induced IL-1β, IL-4, IL-5, IL-6,
IL-12(p40), IFN-γ, CCL2, CCL3, CCL5 and CXCL1 re-
lease into the airways (Table 2). Mavs KO mice also had
significantly reduced IL-22, CXCL9, CXCL10 and MIF
gene expression compared to wild-type mice (Table 3).
Loss of Trif expression altered the RSV induced release
of IL-1β, IL-5, CXCL12 and IFN-γ (Table 2) and airway
gene expression of MIF, LIF and CXCL12 (Table 2).Silencing RIG-I expression in A549 cells subdues cytokine
production
RLRs (RIG-I, MDA5 and LGP2) and Trif were silenced
in A549 cells to establish which RLR signaling was re-
quired for RSV inducible host cytokines (See Additional
file 1: Figure S3 for RLR and Trif knockdown). Loss of
RIG-I expression significantly decreased RSV induced
IL-1β, IL-6, IL-7, IL-12(p70), MCP-1/CCL2, IP-9/
CXCL11, IP-10/CXCL10, TNF-α, MIF, RANTES/CCL5
and SCGF-β (Figure 5). Interestingly, SCGF-β release was
altered following loss of expression of RIG-I, MDA5 and
LGP2 (Figure 5A). CTAK/CCL27 release was only altered
following silencing of MDA5 or Trif expression (Figure 5A).












































Figure 4 Loss of Trif or Mavs expression enhances RSV viral titer in the lungs of mice. (A) RSV infection resulted in a drop in body weight
in all animal groups and (B) a significant increase in the viral load 9 days post RSV challenge in the Mavs KO mouse group compared to mock
treated mice. Graphs are represented as mean ± S.E.M., where each measurement was performed 3 times on 10 animals/group. *Represents a
p value less than 0.05 comparing Mavs KO mice to wild-type mice 9 days post RSV challenge.
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1α/CXCL12 and IL-1β (Figure 5). Therefore, these results
show that host RIG-I is the primary RLR to regulate RSV-
mediated immune responses.
Neutralization LIF enhances lung injury during an
RSV infection
Administration of recombinant LIF to the airways has
a protective effect in response to LPS treatment [32],
hyperoxia [33] and to bacterial pneumonia [29]. The
functional relevance of LIF expression during a RSV
infection is unknown. Administration of anti-LIF IgG
resulted in RSV-infected animals losing weight faster
than control IgG treated littermates (Figure 6A). The
total number of immune cells in the BALF was compar-
able between RSV treated groups (Figure 6B). However,
BALF cells in the animals administered anti-LIF IgG
were undergoing apoptosis at a greater rate than control
IgG animals (Figure 6B). Inhibition of LIF signaling
also subdued RSV induced airway hyperresponsiveness,
demonstrated by respiratory system resistance (Rn)
measurements during a methacholine dose challenge
(Figure 6C). Anti-LIF IgG treated mice had significantly
higher protein concentration (Figure 6D) in the BALF
compared to infected control IgG treated mice, sug-
gesting potentially increased damage and disruption
of the epithelial cell barrier. Lung RSV burdens were
not significantly affected by LIF blockade seven days
following RSV challenge (Figure 6E). Lung cytokine
gene expression was determined by qPCR and blocking
LIF signaling resulted in enhanced CXCL1, RANTES/
CCL5, CXCL10/IP-10, MIP-1α/CCL3 and MCP-1/CCL2compared to control IgG treated mice, 7-days post RSV
infection (Figure 6F). Altogether, these results suggest that
LIF expression suppresses lung cell apoptosis, airway
hyperresponsiveness, epithelial cell barrier damage, cyto-
kine production and subsequently airway injury.
Discussion
To our knowledge, these findings represent the first
evidence that MIF, LIF, CTAK/CCL27, SDF-1α/CXCL12,
SCGF-β and SCF are expressed during an RSV infection
and LIF signaling is critical to prevent lung damage.
Others and we demonstrate that a spectrum of cytokines
is released to counter RSV infection [1,7-10,34] but
further analysis is required to determine the role of these
immune responses in RSV pathology. The results of this
study demonstrate that RLRs and Trif signaling path-
ways play major roles in the immune response to RSV
infection for both inflammation induction and reso-
lution. Interestingly, 34 of the 42 cytokines examined in
A549 and SAE cells were released upon RSV stimulation.
This study highlights the robust epithelial responses to
RSV infection, characterizes two major signaling cascade
needed to counter viral infectivity and identified the role
of LIF signaling during an RSV infection.
Many of the RSV-inducible cytokines described in this
study have already been described in clinical samples,
in vitro epithelial cell culture or in animals models
[1,7-16], such as elevated MIG/CXCL9 levels in BALB/c
mice inoculated with RSV [35]. Importantly, increases in
media or mouse BALF IL1-RA, IL-6, IL-7, CXCL10/
IP-10, CXCL8/IL-8, CCL2/MCP-1, CCL3/MIP-1α, CCL4/
MIP-1β, TNF-α, IFN-γ and CCL5/RANTES following
Table 2 RSV infections induce airway cytokine release in mice
Wild-type Trif KO Mavs KO
Cytokine (pg/ml BALF) Mock RSV Mock RSV Mock RSV
IL-1α 3.54 ± 1.51 30.11 ± 9.64* 9.62 ± 8.57 25.53 ± 5.33 6.74 ± 3.56 24.55 ± 3.36
IL-1β 66.61 ± 5.52 78.55 ± 6.66* 67.05 ± 6.19 66.16 ± 5.00* 56.88 ± 2.83 49.18 ± 4.06#
IL-2 7.25 ± 0.32 5.52 ± 0.31* 6.44 ± 0.03 5.91 ± 1.22 5.36 ± 0.35 6.91 ± 0.75
IL-3 29.39 ± 1.54 28.87 ± 0.84 30.50 ± 1.55 28.95 ± 1.47 22.98 ± 2.89 24.37 ± 0.51
IL-4 15.00 ± 0.01 48.12 ± 0.02* 17.21 ± 0.01 32.89 ± 0.01 14.41 ± 0.01 16.33 ± 0.01#
IL-5 4.15 ± 0.27 20.00 ± 5.42* 5.39 ± 0.63 7.55 ± 1.46# 4.37 ± 0.15 4.81 ± 0.50#
IL-6 3.78 ± 0.44 9.63 ± 3.80* 4.19 ± 0.57 9.79 ± 3.16 3.18 ± 0.31 5.55 ± 1.16#
IL-9 204.10 ± 11.28 233.11 ± 18.25 230.31 ± 37.74 216.01 ± 18.58 181.42 ± 12.58 228.93 ± 19.01
IL-10 61.43 ± 9.92 76.45 ± 22.60 46.08 ± 8.18 166.2 ± 55.5 51.13 ± 8.32 63.33 ± 12.23
IL-12(p40) 8.69 ± 0.17 11.95 ± 1.65* 9.95 ± 0.97 10.99 ± 1.18 6.89 ± 1.06 8.74 ± 0.28#
IL-12(p70) 11.34 ± 0.98 10.23 ± 1.43 13.14 ± 3.60 14.89 ± 2.85 8.60 ± 2.10 12.01 ± 3.70
IL-13 48.41 ± 2.44 29.61 ± 3.50* 41.84 ± 4.94 26.51 ± 2.15 47.99 ± 2.33 30.31 ± 6.52
IL-15 6.96 ± 1.09 14.25 ± 3.31* 13.46 ± 3.62 9.83 ± 1.89 7.42 ± 2.18 10.83 ± 1.68
IL-17 43.66 ± 5.10 64.17 ± 16.72 37.61 ± 30.20 79.81 ± 13.48 41.34 ± 5.01 55.44 ± 4.68
IFN-γ 12.15 ± 0.76 35.47 ± 11.26* 10.19 ± 1.26 8.24 ± 0.61# 11.74 ± 5.04 13.22 ± 3.78#
MCP-1/CCL2 64.57 ± 2.12 85.14 ± 8.23* 67.87 ± 5.15 81.61 ± 7.86 63.22 ± 5.01 69.99 ± 4.82#
RANTES/CCL5 12.41 ± 0.84 107.32 ± 21.70* 18.02 ± 3.32 128.81 ± 23.27 15.01 ± 0.98 68.32 ± 11.90#
TNF-α 524.98 ± 41.34 438.88 ± 55.48 602.71 ± 38.15 460.01 ± 84.64 504.18 ± 32.14 448.88 ± 34.48
MIP-1α/CCL3 105.01 ± 1.38 164.72 ± 5.56* 123.02 ± 18.29 132.58 ± 12.77 95.96 ± 4.84 106.61 ± 4.60#
MIP-1β/CCL4 66.37 ± 2.89 112.91 ± 19.50* 49.59 ± 4.74 103.10 ± 18.43 54.40 ± 10.08 127.45 ± 41.05
MIP-2/CXCL2 10.22 ± 0.56 10.82 ± 2.04 14.86 ± 1.86 13.40 ± 2.47 9.15 ± 0.80 13.00 ± 1.78
Eotaxin/CCL11 5.72 ± 0.55 25.02 ± 5.97* 9.26 ± 2.68 15.37 ± 3.80 5.94 ± 0.50 13.62 ± 3.08
GM-CSF/CSF2 41.63 ± 3.79 45.57 ± 3.25 49.61 ± 3.60 57.88 ± 6.41 37.14 ± 6.15 45.93 ± 2.41
M-CSF/CSF1 24.93 ± 2.08 26.73 ± 2.47 29.13 ± 2.97 28.85 ± 3.79 20.40 ± 1.97 25.94 ± 2.84
LIF 12.37 ± 5.4 70.18 ± 12.33* 11.12 ± 2.12 60.42 ± 10.32 12.91 ± 3.99 72.32 ± 7.69
CTAK/CCL27 231 ± 21.23 430 ± 43.21* 220 ± 18.91 389.1 ± 21.98 198.3 ± 10.99 424.7 ± 34.76
SDF-1α/CXCL12 94.0 ± 10.16 312.2 ± 50.96* 51.1 ± 23.23 77.21 ± 13.11# 110.21 ± 20.20 296.19 ± 15.07
SCF 711.00 ± 40.15 1713.06 ± 98.19* 721.79 ± 88.95 1392.90 ± 99.41 702.83 ± 76.41 1721.22 ± 70.60
GROα/KC/CXCL1 1.02 ± 0.45 81.35 ± 16.70 1.24 ± 0.16 81.29 ± 23.27 4.35 ± 0.97 48.55 ± 20.84#
Cytokine levels were determined in BALF from wild-type, Trif KO and Mavs KO mice 3 days post RSV challenge, by multiplex analysis. Values are represented as
mean BALF concentration (pg/ml) ± S.E.M. Each assay was performed in triplicate, where n = 10 animals/group. Bold numbers denoted by *represents a p value
less than 0.05 compared to mock treated mice. #denotes a p value less than 0.05 compared to RSV treated wild-type mice.
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studies [10,36]. To our knowledge, we are the first to iden-
tify that RSV infection in epithelial cells and mice can in-
duce MIF, LIF, CTAK/CCL27, SDF-1α/CXCL12, SCGF-β
and SCF expression and secretions. This is an important
finding as each new target can potentially play a different
role in RSV clearance. MIF activates lymphocytes, granu-
locytes and monocytes/macrophages and plays a key role
in several host immune cell responses [37]. CTAK/CCL27
is a cytokine associated with T cell activation and migra-
tion [38] and is elevated in severe tuberculosis cases [39].
Recombinant protein SDF-1α/CXCL12 does not prevent
RSV infection of Hep2 cells [40] but SDF-1α/CXCL12 isstrongly chemotactic for lymphocytes [41] and contributes
to pulmonary fibrosis [42]. The potential role of SCGF-β
in RSV infections is not as straightforward to elucidate but
SCGF-β can support growth of primitive hematopoietic
cells [43] and can promotes proliferation of erythroid or
myeloid progenitors. SCF and its soluble receptor c-kit
correlate with asthma severity [44]. This study identified
an important role for LIF in RSV infection. Therefore,
identifying these new RSV inducible targets in clinical
samples and their role in viral clearance may provide
important insights into host responses to RSV infection.
Other investigators have demonstrated the thera-
peutic potential of LIF expression in other models of
Table 3 RSV infections enhance airway cytokine gene expression
Wild-type Trif KO Mavs KO
Cytokine (pg/ml) Mock RSV Mock RSV Mock RSV
IL-4 1.00 ± 0.40 4.67 ± 1.26* 1.26 ± 0.33 3.97 ± 0.53 0.27 ± 0.14 0.23 ± 0.10#
IL-6 1.00 ± 0.10 4.15 ± 0.14* 1.30 ± 0.33 3.32 ± 0.52 1.81 ± 0.71 1.61 ± 0.57#
IL-18 1.00 ± 0.19 0.71 ± 0.16 0.64 ± 0.15 0.43 ± 0.03 0.51 ± 0.06 0.60 ± 0.34
IL-22 1.00 ± 0.41 1.19 ± 0.16 0.98 ± 0.07 1.49 ± 0.49 0.54 ± 0.30 0.45 ± 0.08#
IL-23 1.00 ± 0.41 1.48 ± 0.27 0.75 ± 0.17 1.41 ± 0.20 0.19 ± 0.15 1.03 ± 0.02
IL-27 1.00 ± 0.15 2.00 ± 0.10* 0.98 ± 0.31 1.88 ± 0.39 0.49 ± 0.06 1.63 ± 0.09
CXCL1/KC 1.00 ± 0.12 11.91 ± 0.05* 1.56 ± 0.67 12.04 ± 0.37 0.29 ± 0.11 3.23 ± 0.12#
MIG/CXCL9 1.00 ± 0.58 160.81 ± 17.67* 3.18 ± 1.10 148.83 ± 16.68 0.23 ± 0.14 29.47 ± 5.42#
IP10/CXCL10 1.00 ± 0.18 8.07 ± 1.62* 1.78 ± 0.43 9.77 ± 2.51 0.312 ± 0.10 3.59 ± 2.07#
IP9/CXCL11 1.00 ± 0.12 2.61 ± 0.26* 1.30 ± 0.44 4.38 ± 0.85 0.18 ± 0.16 3.19 ± 1.05
MIF 1.00 ± 0.19 2.40 ± 0.26* 1.09 ± 0.15 0.90 ± 0.41# 0.93 ± 0.11 0.52 ± 0.40#
LIF 1.00 ± 0.14 2.71 ± 0.09* 1.16 ± 0.66 1.01 ± 0.27# 0.99 ± 0.11 2.43 ± 0.13
CTAK/CCL27 1.00 ± 0.28 5.79 ± 0.67* 1.18 ± 0.18 4.23 ± 0.68 0.73 ± 0.18 4.27 ± 0.42
SDF-1α/CXCL12 1.00 ± 0.16 2.67 ± 0.96* 1.28 ± 0.23 1.57 ± 0.51# 0.51 ± 0.20 2.59 ± 1.07
SCGF-β 1.00 ± 0.22 1.87 ± 0.16* 1.33 ± 0.14 1.88 ± 0.81 0.88 ± 0.26 1.19 ± 0.15
SCF 1.00 ± 0.15 1.60 ± 0.16* 1.09 ± 0.25 1.20 ± 0.41 0.93 ± 0.11 1.82 ± 0.40
TGF-β 1.00 ± 0.16 1.47 ± 0.06 0.84 ± 0.19 1.00 ± 0.43 0.51 ± 0.01 0.62 ± 0.43
MCP-1/CCL2 1.00 ± 0.08 12.39 ± 3.01* 2.38 ± 0.73 20.45 ± 4.31 0.45 ± 0.07 5.13 ± 1.33#
MIP-1α/CCL3 1.00 ± 0.08 10.17 ± 1.51* 1.68 ± 0.40 13.64 ± 1.51 0.58 ± 0.14 3.37 ± 0.83#
Cytokine gene expression levels were determined in lung tissue from wild-type, Trif KO and Mavs KO mice 1 days post RSV challenge by qPCR, except CTAK/
CCL27 which was examined 5 days post RSV challenge. Values are represented as mean RQ (relative to mock treated animals, using β-Actin as an endogenous
control.) ± S.E.M. Each assay was performed in triplicate, where n = 10 animals/group. Bold numbers denoted by *represents a p value less than 0.05 compared to
mock treated mice. #denotes a p value less than 0.05 compared to RSV treated wild-type mice.
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Recombinant LIF reduces cytokine expression [29] and
alters alveolar neutrophil numbers [29,32]. Lif KO ani-
mals have increased expression of CXCL1, GM-CSF,
RANTES/CCL5 and MIP-1α/CCL3 early during an
experimental autoimmune encephalomyelitis model and
reduced CCL2, CCL3, and CXCL10 at a later stage of the
disease [45]. In this study neutralizing LIF signaling
enhanced CXCL1, RANTES/CCL5, CXCL10/IP-10, MIP-
1α/CCL3 and MCP-1/CCL2 at day 7 of an RSV infection.
Therefore LIF expression has the potential to regulate
key factors in the immune system. Targeted overexpres-
sion of LIF in mouse airway epithelial cells significantly
protects the airways during hyperoxia, with improved
survival and decreased pulmonary edema [33]. Other
IL-6 family members (IL-6 [46] and IL-11 [47]) have
similar functions, which suggest that IL-6 family cyto-
kines may collectively protect lungs from injury. LIF is a
prominent STAT3-activating cytokine that facilitates tis-
sue protection during pneumonia [29] and plays a similar
airway protective role during RSV infection. The signifi-
cance of LIF expression and STAT3 activation in RSV in-
fection represents an intriguing area for further study.
LIF has been shown to regulate apoptosis with someinvestigators suggesting LIF acts as a pro-apoptotic medi-
ator [48,49] while others have demonstrated LIF to have
anti-apoptotic potential [50,51]. In this study increased
apoptotic BAL cells were observed in animals adminis-
tered anti-LIF IgG prior to RSV infection. Enhanced Fas,
Fap, Il24, and Tnfsf15 expression is observed following
LIF depletion in animals with bacterial pneumonia [29],
which could contribute to the increased apoptosis ob-
served here. Whether this induction of apoptosis contrib-
utes to the pathology observed in this study is unknown
and requires further investigation. Epithelial damage cor-
relates with airway hyperreactivity in asthma patients
[52] and the increased protein levels in the BALF of ani-
mals treated with anti-LIF IgG prior to RSV infection
could also contribute to the enhanced airway resistance
observed in these animals. LIF enhances the maintenance
of stem cells [27], which may directly impact lung tissue
regeneration and repair [53], similar to IL-6 activation of
STAT3 [54]. These data reveal the vast biological pro-
cesses of LIF signaling during RSV infection. Whether
the other cytokines identified in this study also play such
major roles on disease pathology needs to be addressed.
Our study also reveals that Trif and RLR signaling
























































































































































































































































Figure 5 (See legend on next page.)
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Figure 5 Silencing RIG-I subdues RSV induced cytokine release from A549 cells. (A-B) Multiplex or ELISA analysis was performed on secreted
cytokines from A549 cells transfected with siRNA targeting RIG-I (DDX58), LGP2 (DHX58), MDA5 (IFIH1), Trif or a negative sequence control. Graphs are
represented as mean cytokine concentration ± S.E.M, where n = 10 replicates/group and each assay were performed in triplicate. Each experiment was
performed on samples obtained from 3 experiments from separate days. *Represents a p value less than 0.05 compared to control siRNA treated cells
following RSV infection.
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activation. Prior to undertaking this study, several
pathogen recognition receptors were associated with
regulating the immune response against RSV infection,
with RIG-I [55], TLR7 [56] and TLR3 [57] known to
affect numerous cytokine responses. Several investiga-
tors characterized the RIG-I-like family proteins as crit-
ical for the detection of RSV, using human cell lines
[30] and knockout mice [58]. RIG-I principally recog-
nizes dsRNA [59]; however Sendai virus defective inter-
fering RNA [60] and the genomic “panhandle” structure
of influenza virus [61] activate RLR signaling. These
“panhandle” structures allow negative-strand RNA viral
genomes to achieve partially double-stranded RNA [62],
which may allow RSV to induce RLRs. Our study ob-
served early cytokine responses following RSV infection
and identified a pronounced RIG-I response, which could
be lost over time following NS1 or NS2 binding to RIG-I/
MDA5 as reported by others [63,64]. Also, RSV induc-
tion of TLR3 is regulated by RIG-I-dependent IFN-β
secretions from infected epithelial cells, which is medi-
ated by both IFN response-stimulated element (ISRE)
and signal transducer and activator of transcription
(STAT) sites in its proximal promoter [65]. Therefore
there are multiple levels of RLRs regulation in RSV
infections that can both trigger RLRs responses or sub-
sequently adapt to block RLR-mediated signaling.
Recently, several investigators have utilized well-
defined primary cell culture techniques to investigate
viral-host interactions [1,66,67], which may be a closer
representation of human RSV infections compared to
the approach we employed here. IFN-α/β are not se-
creted by RSV-infected well-defined bronchial epithelial
cells [66], suggesting that there could be major signaling
differences in well-defined primary cell culture tech-
niques and monolayers. However, our overall findings
suggest that utilizing cell monolayers in combination
with mouse models is an acceptable approach as our
cytokine profile are comparable to that observed in the
human disease state [10]. In addition, our study has ex-
posed new RSV inducible host immune response cyto-
kines. Since we only explored epithelial cell responses
in vitro, our in vivo parallel approach also validates our
monolayer results and suggests that the epithelium is a
significant source of initial immune responses following
RSV infection.Conclusions
Our studies demonstrate that RSV exposure stimulates a
cascade of early immune response in epithelial cells and
a large number of these responses act in an RLR/Trif
dependent manner. These findings also identified new
cytokines that are triggered by RSV lung infection, with
LIF signaling critical for the protection of the lung from
injury during RSV infection. Profiling the loss and gain
of the other identified cytokines (MIF, CTAK/CCL27,
SDF-1α/CXCL12, SCGF-β and SCF) over the course of
an RSV infection may help to decipher the relevancy of
these cytokines in viral clearance and lung integrity, and




Human RSV strain A2 (ATCC, Manassas, VA; #VR-
1540) was infected at a multiplicity of 0.1 into Hep2
cells. The virus was allowed to grow for 5 days at 37°C
in a 5% CO2 atmosphere. The infected Hep2 monolayers
were collected and the virus was released by sonication.
Cell debris was removed by centrifugation at 2500 × g
for 5 minutes at 4°C. Virus was collected by centrifuging
the supernatant for 2 hours at 22000 × g at 4°C. Virus
were suspended in culture media and snap frozen and
maintained at −80°C. Infectious virus titers were deter-
mined on Hep2 cells by performing serial dilution of the
RSV stocks and counting infected cells stained for indir-
ect immunofluorescence with an RSV F-specific mono-
clonal antibody (Abcam, Cambridge, MA). Additionally,
plaque assays were performed as previously described
[68] on Hep2 cells using methyl cellulose overlay media
and staining with 0.5 mg/ml thiazolyl blue tetrazolium
bromide (MTT; Sigma Aldrich) solution for 3 hours at
37°C. Non-infected cells were processed in the same
manner as RSV infected cells and the resulting sample
collection was used as a mock control. For experiments
examining the effects of non-infectious RSV (UV-RSV),
RSV preparations were UV-inactivated.
Cell culture
Monolayers of human SAE cells (Lonza, Walkersville,
MD) from healthy subjects and A549 cells were cultured
under submerged conditions. SAE cells were used for
experiments at passages 3–6 and at a confluency of
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  7 days post RSV challenged
Figure 6 RSV induced airway injury is enhanced following LIF neutralization. FVB/NJ mice were IP injected with control IgG or anti-LIF IgG prior
to intranasal infected with 1x106 pfu of RSV and animals were euthanized 7-days post infection. (A) Animal body weight, (B) BALF cellularity and BALF
cells undergoing apoptosis were determined. (C) Airway hyperresponsiveness to increasing doses of methacholine was assessed in each animal group.
(D) RSV infected animals receiving anti-LIF IgG have enhanced protein content in BALF compared to mice administered control IgG. (E) Neutralizing
LIF levels did not impact on RSV viral multiplicity, demonstrated by qPCR for RSV N. (F) CXCL1, RANTES, CCL5, CXCL10/IP-10, MIP-1α/CCL3 and MCP-1/
CCL2 gene expression in lung tissue was analyzed by qPCR. Graphs are represented as mean ± S.E.M., where each measurement was performed 3 times
on 10 animals/group. * represents a p value less than 0.05 comparing control IgG and anti-LIF IgG treated mice both infected with RSV.
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multiplicity of infection (MOI) of 0.3 for 24 hours.
Immunoreactivity assays were performed on SAE andA549 cells with polyclonal anti-RSV (Abcam; ab20745)
antibodies. Cells were also treated with mock control, as
described above. Additionally, A549 cells SAE cells were
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http://www.biomedcentral.com/1471-2172/15/41transfected by administering siRNA for MDA5, RIG-I,
LGP2, Trif or control siRNA (Qiagen, Gaithersburg, MD).
Animal models
Trif (Ticam1) and Mavs knockout (KO) mice were pur-
chased from the Jackson Laboratory (Bar Harbor, ME)
and bred on to a FVB/NJ background at least 6 genera-
tions. All mice were maintained in a specific pathogen-
free facility at Mount Sinai Roosevelt Hospital. 8-week-old
mice were used at the initiation point for all experiments
and each experimental parameter had 10 animals/group.
Mice were anesthetized by intraperitoneal (IP) injection of
a mixture of ketamine and xylazine. Animals were intrana-
sally administered 1×106 PFU RSV or mock. Animals were
euthanized on days 0, 1, 3, 5, 7 and 9 post RSV or mock
administering. Bronchoalveolar lavage fluid (BALF) and
tissues were collected for cytokine analysis. FVB/NJ mice
were IP injected with 100 μg of normal goat IgG (R&D
Systems) or a neutralizing goat polyclonal IgG targeting
murine LIF (R&D Systems) 2 hours prior to RSV ad-
ministration. Lung viral titer and RSV N copy number
were determined as previously described [69]. BALF
cells were analyzed for apoptosis utilizing the LIVE/
DEAD cell viability assay from Life Technologies on
the Guava easyCyte flow cytometer from Millipore. All
animal experiments were performed with approval from
Mount Sinai Roosevelt’s Hospital’s Institutional Animal
Care and Use Committee approval.
Cytokine measurements
Mouse IL-4, IL-6, IL-18, IL-22, IL-23, IL-27, CXCL1/KC,
CXCL9, CXCL10/IP-10, CXCL11, MIF, TGF-β, CCL2,
LIF, CXCL12, CCL27, SCGF-β, SCF, MCP-1/CCL2,
RANTES/CCL5 and MIP-1α/CCL3 gene expression was
performed by quantitative PCR (qPCR) using Taqman
probes (Life technologies/Applied Biosystems, Carlsbad,
CA). 42 human and 26 mouse cytokines were examined
in human cell media and mouse BALF, respectively,
using beads assays (Bio-Rad Magnetic Cytokine Bead
Panels, groups 1 and 2) with the BioRad Bio-Plex 200
system (BioRad, Hercules, CA). ELISAs were utilized
to determine mouse CXCL12 (R&D systems), CCL27,
SCGF-β and SCF (Abcam) BALF levels.
Intracellular signaling
Cells were lysed in radio-immunoprecipitation assay
(RIPA) buffer, centrifuged at 13,000 × g for 10 minutes
and supernatants collected. Immunoblots were conducted
to determine levels of p-IRF3(ser396), IRF3, p-TBK1/NAK
(Ser172), TBK1/NAK, RIG-I, MDA5, LGP2, TLR2, TLR3,
TLR7, TLR8, TLR9, Trif, MyD88, IRAK1, NOD2 and actin
(all antibodies from Cell Signaling Technologies). TLRs,
NOD1, NOD2, NXLR1, RIG-I, MDA5, Trif and actinexpressions were determined by qPCR using Taqman
probes (Life technologies/Applied Biosystems).
Airway responses to methacholine challenge
Airway responses to methacholine (Sigma Chemical, St.
Louis, MO) were assessed with the Scireq Flexivent sys-
tem (Scireq, Montreal, QC, Canada) 1-week post RSV
challenge and IP injection of control IgG or anti-LIF
IgG. Animals were anesthetized with ketamine/xylazine
(10 mg/kg) and paralysis was induced with 1 mg/kg
pancuronium bromide IP (Sigma). The linear single-
compartment model was used to assess total respiratory
system resistance (Rn). Methacholine dose responses were
determined.
Statistical analyses
For statistical analysis, data from 10 animals or multiple
separate cell experiments were pooled. Data are expressed
as means ± S.E.M. Differences between groups of mice
over time were compared by two-way analysis of variance
(ANOVA). Individual differences between groups were
tested by multiple comparison and analysis using the
Bonferroni post-test. Pairs of groups were compared by
Student’s t test (two tailed). p values for significance were
set at 0.05. All analysis was performed using GraphPad
Prism Software (Version 5 for Mac OS X).
Additional file
Additional file 1: Figure S1. Profiling A549 cell cytokine response
utilizing protein arrays. A549 cells were infected at an MOI of 0.3 for
24 hours. Cytokine arrays were performed with 24-hour media from
mock and RSV treated cells. Densitometry were performed. Each pair
of horizontal spots represents one cytokine. Graphs are represented
as mean pixel intensity ± S.E.M, where n=2 spots/group and each
assay were performed on 3 samples/group collects on separate days.
Figure S2. Quantification of pathogen recognition receptors and kinase
immunoblots of RSV treated A549 and SAE cells. (A) SAE and (B) A549 cells
were treated with mock or RSV (MOI of 0.3) for 24 hours. Immunoblots
(from Figure 3B) were subjected to densitometry analysis. Graphs are
represented as mean pixel intensity (ratios of total protein to actin or
phosphorylated protein to total protein)± S.E.M, where n=3 replicates/
group and each assay were performed on samples obtained on multiple
days (3) and from multiple immunoblots. Figure S3. Confirmation
that expression of Trif and RLRs was silenced in A549 cells. A549 cells
were transfected with siRNA targeting RIG-I (DDX58), LGP2 (DHX58),
MDA5 (IFIH1), Trif or a negative sequence control. Immunoblots were
performed to determine RIG-I, LGP2, MDA5 and Trif protein levels compared
to actin.
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